Saturday 17 October 2026 Export VSTM’s income statement to Excel — free account

Verastem, Inc.

Verastem, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $30.9 million, up 209.1% from fiscal 2024. In the quarter to June 2026, revenue grew 1,775.4%, EPS grew 10.3%, free cash flow fell 34.4% and total debt was flat, each against the same quarter a year earlier.

8.65 0.58 −6.28%

Follow VSTM

Alert me

Market cap: $835.9M
P/E: 0.0×
Fwd P/E: −2.4×
Dividend yield: —
F-score: n/a
Altman Z: −6.34
Beneish M: 10.74
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total sells 1.09

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	5	7	2	1	—	—	1	2	—	1	1	2

Insider Ownership 18.10%

Capital & Financial Ratios $m

Market Cap 835.90

Revenue 87.53

Net Income (202.70)

Free Cash Flow (162.19)

Net Debt (62.58)

Current Ratio 2.25

Debt/Equity 1.48

P/E ratio 0.00

Fwd P/E (2.38)

P/S ratio 9.89

P/B ratio 17.32

Past 5Y EPS Growth —

This Y EPS Growth 45.81%

Next Y EPS Growth 7.57%

Next Y revenue growth 275.23%

Next 5Y EPS Growth 22.60%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 39.99%

10-year low 10-year high

P/B against its own 10 years 97.07%

10-year low 10-year high

EV/Sales against its own 10 years 54.96%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2023	Powerpack
2022	Powerpack
2021	Powerpack
2020	Powerpack
2019	Powerpack
2017	Powerpack

special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	137	89	205	136
Receivables	—	0	9	29
Inventory	—	—	2	2
Other	—	—	—	—
	144	95	223	176

	2023	2024	2025	Q'26
Payables	7	4	12	18
ST’ Debt	—	—	—	—
Other	0	—	5	5
	26	31	72	78

Compound Annual Growth %

	10y	5y	3y
Sales	—	12.11%	146.94%
Cash Flow	0.00%	0.00%	0.00%
Earnings	0.00%	0.00%	0.00%
Book Value	(5.66%)	(13.08%)	6.47%

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	19	40	—	—	—
’25	—	2	11	18	31
’24	—	10	—	—	10
’22	3	—	—	—	3
’21	1	1	0	1	2
’20	5	4	79	1	89
’19	2	3	9	4	17

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(52)	(44)	—	—	—
’25	(39)	(33)	(36)	(30)	(138)
’24	(28)	(28)	(24)	(25)	(105)
’23	(20)	(20)	(17)	(30)	(86)
’22	(19)	(13)	(15)	(17)	(64)
’21	(19)	(13)	(11)	(10)	(54)
’20	(34)	(23)	45	(22)	(34)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(52)	(44)	—	—	—
’25	(39)	(33)	(44)	(31)	(147)
’24	(28)	(28)	(24)	(25)	(105)
’23	(20)	(20)	(17)	(30)	(86)
’22	(19)	(13)	(15)	(17)	(64)
’21	(20)	(13)	(11)	(10)	(54)
’20	(34)	(23)	45	(22)	(34)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(0.46)	(0.35)	—	—	—
’25	(0.96)	(0.39)	(1.35)	(0.50)	(3.02)
’24	(1.26)	(0.31)	(0.60)	(1.49)	(3.66)
’23	(0.96)	(1.37)	(0.75)	(1.02)	(3.96)
’22	(1.08)	(1.44)	(1.08)	(0.96)	(4.56)
’21	(1.08)	(1.20)	(1.56)	(1.08)	(4.92)
’20	(4.20)	(1.68)	0.96	(1.44)	(5.28)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	12.60	13.32	33.24	9.96	12.96	22.44	3.48	4.20	2.10	4.01	Analyst estimates 2026–2028 Powerpack
	High	23.16	68.52	124.20	51.00	56.04	59.16	25.56	15.12	14.22	11.25
People
People	Employees	32	69	169	135	48	48	57	73	78	102
	Revenue/emp, $m	0.00	0.00	0.16	0.13	1.84	0.04	0.05	0.00	0.13	0.30
Income, $m
Income, $m	Revenue	—	—	27	17	89	2	3	—	10	31
	Gross margin, %	0.00	0.00	97.80	83.92	61.88	100.00	100.00	—	100.00	82.86
	EBT	(36)	(68)	(72)	(149)	(68)	(71)	(74)	(87)	(130)	(209)
	EBT margin, %	0.00	0.00	(271.11)	(854.77)	(76.29)	(3,468.10)	(2,843.30)	0.00	(1,304.52)	(677.59)
	Net income	(36)	(68)	(72)	(149)	(68)	(71)	(74)	(87)	(131)	(209)
	Depreciation	1	1	3	9	12	9	0	(1)	0	1
Per share, $
Per share, $	Revenue	0.00	0.00	4.94	2.81	6.93	0.14	0.16	0.00	0.28	0.45
	Earnings	(11.88)	(21.13)	(13.44)	(24.01)	(5.28)	(4.92)	(4.56)	(3.96)	(3.66)	(3.02)
	Cash flow	(9.57)	(17.91)	(13.77)	(22.30)	(2.62)	(3.68)	(3.95)	(3.92)	(2.93)	(1.98)
	Capex	(0.01)	0.00	(4.33)	0.00	0.00	(0.01)	0.00	0.00	0.00	(0.14)
	Free cash flow	(9.58)	(17.91)	(18.10)	(22.30)	(2.63)	(3.69)	(3.95)	(3.92)	(2.93)	(2.12)
	Book value	23.46	18.02	22.97	1.15	9.03	6.02	2.94	3.56	(0.81)	0.83
	Shares, m	3	3	5	6	13	15	16	22	36	69
Valuation, ×
Valuation, ×	P/E	—	—	0.00	0.00	0.00	0.00	0.00	—	0.00	0.00
	P/S	—	—	0.00	5.72	3.69	174.17	22.33	—	14.05	13.08
	P/B	—	—	1.76	13.92	2.83	4.08	1.72	—	0.00	9.35
	EV/Sales	—	—	0.00	7.36	2.31	125.78	5.23	—	11.14	10.17
	EV/FCF	—	—	(1.17)	(0.92)	(6.11)	(4.81)	(0.30)	—	(1.40)	(3.03)
Cash, $m
Cash, $m	Operating cash flow	(29)	(57)	(75)	(139)	(34)	(54)	(64)	(86)	(105)	(138)
	Capex	0	—	(23)	0	0	0	—	—	0	(10)
	Free cash flow	(30)	(57)	(98)	(139)	(34)	(54)	(64)	(86)	(105)	(147)
Balance, $m
Balance, $m	Working capital	70	71	216	55	128	87	71	117	64	151
	Total debt	—	15	120	104	19	0	25	40	41	76
	Net debt	(81)	(72)	(129)	28	(122)	(100)	(63)	(97)	(48)	(129)
	Shareholders’ equity	72	58	124	7	115	88	47	79	(29)	57
Returns, %
Returns, %	ROA	(37.05)	(78.19)	(39.47)	(70.67)	(45.24)	(54.14)	(72.47)	(71.39)	(103.99)	(120.39)
	ROIC	0.00	0.00	0.00	(234.37)	0.00	0.00	0.00	0.00	0.00	0.00
	ROE	(41.70)	(104.33)	(79.61)	(226.98)	(110.62)	(70.21)	(109.39)	(166.79)	(917.36)	(1,480.15)

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
MLTX MoonLake Immunotherapeutics	$873.2M	— (loss-making)	—	—	n/m	−1.89% (below 0%: shrinking)	0.00%	0.00%	Compare
GLUE Monte Rosa Therapeutics, Inc.	$863.4M	— (loss-making)	— (loss-making)	−61.33% (below 0%: shrinking)	n/m	−34.11% (below 0%: shrinking)	100.00%	(547.84%)	Compare
KURA Kura Oncology, Inc.	$862.9M	— (loss-making)	— (loss-making)	+36.54% (above 0%: growing)	n/m	−109.05% (below 0%: shrinking)	98.84%	(349.77%)	Compare
ALMS Alumis Inc.	$842.4M	— (loss-making)	— (loss-making)	−37.66% (below 0%: shrinking)	n/m	+23.59% (above 0%: growing)	100.00%	(8,956.38%)	Compare
VSTM Verastem, Inc.	$835.9M	— (loss-making)	— (loss-making)	+1,775.43% (above 0%: growing)	n/m	−34.43% (below 0%: shrinking)	89.92%	(81.62%)
CRVS Corvus Pharmaceuticals, Inc.	$828.6M	— (loss-making)	—	—	n/m	−171.31% (below 0%: shrinking)	0.00%	0.00%	Compare
AVBP ArriVent BioPharma, Inc.	$827.9M	— (loss-making)	—	—	n/m	−51.51% (below 0%: shrinking)	—	0.00%	Compare
ARDX Ardelyx, Inc.	$814.9M	— (loss-making)	— (loss-making)	+23.77% (above 0%: growing)	n/m	+75.33% (above 0%: growing)	95.24%	(10.28%)	Compare
HELP Cybin Inc.	$807.3M	— (loss-making)	— (loss-making)	—	n/m	−25.60% (below 0%: shrinking)	0.00%	0.00%	Compare
Median of peers	$835.5M	—	—	−6.94%	—	−29.85%	95.24%	(5.14%)

All 614 Biotechnology stocks →

Verastem, Inc. (VSTM) key facts

Strength: Verastem, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $30.9 million, up 209.1% from fiscal 2024.
Verastem, Inc. (VSTM) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
As of October 16, 2026, VSTM traded at $8.65, a market capitalization of $835.9 million.
Return on equity was −1,480.2% and debt-to-equity 1.48.
Its Altman Z-score is −6.34 (distress zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.